Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Upgraded by StockNews.com

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "sell" rating to a "hold" rating in a research report issued on Wednesday.

A number of other equities analysts also recently weighed in on ENTA. HC Wainwright dropped their price target on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday. JPMorgan Chase & Co. cut their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an "underweight" rating for the company in a research note on Thursday, February 8th. Finally, JMP Securities lowered their price target on Enanta Pharmaceuticals from $23.00 to $22.00 and set a "market outperform" rating for the company in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $19.00.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock traded down $0.34 during mid-day trading on Wednesday, hitting $12.76. The company's stock had a trading volume of 160,469 shares, compared to its average volume of 244,025. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $28.25. The firm's 50 day moving average is $14.88 and its 200 day moving average is $12.08. The company has a market cap of $269.95 million, a PE ratio of -2.04 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. As a group, analysts forecast that Enanta Pharmaceuticals will post -4.9 EPS for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pennant Investors LP acquired a new stake in Enanta Pharmaceuticals in the 4th quarter worth approximately $330,000. Quest Partners LLC acquired a new stake in Enanta Pharmaceuticals in the 4th quarter worth approximately $146,000. Federated Hermes Inc. acquired a new stake in Enanta Pharmaceuticals in the 4th quarter worth approximately $1,253,000. Strs Ohio lifted its holdings in Enanta Pharmaceuticals by 20.6% in the 4th quarter. Strs Ohio now owns 18,700 shares of the biotechnology company's stock worth $175,000 after purchasing an additional 3,200 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in Enanta Pharmaceuticals by 417.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 2,281 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.